Martin Himmel brings over 25 years of regulatory affairs experience and responsibilities which have included products spanning a number of different therapeutic areas, drugs, biologics, devices, promotional review and digital health.
Following a number of years of clinical work, Martin worked at the FDA where he had review and management responsibilities in the Division of Pulmonary Drug Products and in the FDA Office of Drug Safety. After 12 years at the FDA, he moved to the industry where he worked at Merck and then at Novo Nordisk where he held various executive regulatory affairs roles.
Martin holds an MD from the Albert Einstein College of Medicine in the US and is trained as a physician in internal medicine. In addition, he earned a Master’s degree in Public Health from the Johns Hopkins University School of Public Health.